Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc., a pharmaceutical company specializing in light-activated treatments, is set to present interim clinical data from their Phase II study at upcoming advisory board meetings with top urologists in Canada and the U.S. The data highlights the potential of their Ruvidar-based therapy as a significant advancement in treating BCG-Unresponsive Non-Muscle Invasive Bladder Cancer, aiming to offer a new, effective treatment alternative to surgery.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
